New GLP-1 Drugs in 2026: What Just Got Approved & What's Still in the Pipeline

New GLP-1 Drugs in 2026: What Just Got Approved & What's Still in the Pipeline

The GLP-1 drug landscape just changed significantly.

Key Takeaways

• Two new oral options approved: The Wegovy 50mg pill and orforglipron (Foundayo) both reached approval — oral delivery is no longer experimental.
• No fasting vs. fasting: Orforglipron can be taken with food; oral semaglutide 50mg requires a 30-minute fast and minimal water. That distinction matters for real-world adherence.
• Pipeline is approaching bariatric territory: Retatrutide and CagriSema are posting Phase 2/3 weight loss numbers — 24–25% — that match what gastric sleeve surgery produces on average.
• Pipeline timelines are routinely optimistic: Phase 3 completion to FDA approval typically takes 2–4 years from when Phase 3 starts — "coming in 2026" for most pipeline drugs is unlikely to mean available in 2026.
• Mechanism diversity is expanding: Amylin analogues, GIP, and glucagon receptor targets are now being layered onto GLP-1 agonism in ways that could redefine the obesity treatment ceiling.

If you last evaluated your options in 2023 or 2024, you were working with a different menu than exists now — and the menu will look different again in 18 months. Two new oral GLP-1 drugs have received approval, multiple pipeline compounds are producing weight loss numbers that parallel surgical outcomes, and a structural shift toward non-injectable options is underway. Here is what has changed, what is in trials, and how to read the timelines honestly.

What just became available: oral semaglutide 50mg (Wegovy pill)

Oral semaglutide 50mg received FDA approval for chronic weight management — the first oral GLP-1 therapy approved specifically for obesity, not just type 2 diabetes. The existing Rybelsus (oral semaglutide 14mg) was approved for T2D only; the 50mg dose and Wegovy pill formulation extends that indication to obesity in adults with BMI of 30 or above, or 27 with a weight-related comorbidity.

The OASIS 1 trial enrolled adults with obesity but without type 2 diabetes. At 68 weeks, participants taking the 50mg dose lost an average of ~15% of body weight — comparable to the injectable Wegovy 2.4mg result in STEP 1. That comparable outcome is notable because oral semaglutide's bioavailability is approximately 1% versus ~89% for the subcutaneous form. The SNAC delivery technology and the higher absolute dose compensate for the absorption difference.

The Wegovy pill requires strict dosing conditions: take it on an empty stomach, with no more than 120mL (about half a cup) of water, at least 30 minutes before the first food, drink, or other oral medication of the day. These are not preferences — they are pharmacokinetic requirements. Clinical data shows that taking the tablet with 240mL of water cuts exposure by approximately 30%. Non-compliance with the fasting window can substantially reduce efficacy over time.

What just became available: orforglipron (Foundayo)

Orforglipron from Eli Lilly is a different kind of oral GLP-1 drug — not a peptide analogue but a non-peptide small molecule. This structural difference has a practical consequence that matters daily: you can take it with or without food, at any time of day, with a normal amount of water. There is no SNAC mechanism, no stomach permeability window to optimize, no 30-minute morning ritual.

Phase 3 data showed approximately 14.7% weight loss at 36 weeks for the highest dose, with continued weight loss trajectory suggesting the 68-week number would be in the same vicinity as injectable semaglutide. The side effect profile is qualitatively similar to other GLP-1 agents — nausea, vomiting, diarrhea, primarily during dose escalation — but some patients report the GI effects are less intense than with peptide-based agents, possibly because the receptor activation kinetics differ for a small molecule.

Orforglipron's approval marks a genuine structural shift: for needle-averse patients, or those for whom injection logistics create adherence barriers, a full-efficacy oral GLP-1 option now exists without the dosing constraints of the Wegovy pill.

The pipeline: retatrutide

Retatrutide (Eli Lilly) is a once-weekly injectable triple agonist that simultaneously activates GLP-1R, GIPR, and the glucagon receptor (GCGR). Adding glucagon receptor agonism to the GLP-1/GIP combination is the theoretical basis for higher efficacy: GCG activation increases energy expenditure and fat oxidation — the body burns more even at rest — on top of the appetite suppression driven by GLP-1 and GIP.

Phase 2 results at 48 weeks showed 24.2% average body weight loss at the 12mg dose. Phase 3 is ongoing. For context: a 24% average weight loss from a weekly injection would exceed what gastric banding produces and approach what sleeve gastrectomy produces on average (~25–30%). If Phase 3 confirms Phase 2, retatrutide would represent the highest-efficacy approved pharmacotherapy for obesity by a significant margin. Phase 3 completion is expected in 2025–2026; FDA review would add at least another 6–12 months after that.

The pipeline: CagriSema

CagriSema is Novo Nordisk's combination of semaglutide and cagrilintide (a long-acting amylin analogue) in a single weekly injection. Amylin is a pancreatic hormone co-secreted with insulin that independently suppresses appetite and slows gastric emptying — a complementary mechanism to GLP-1. The hypothesis is that combining two satiety hormones with different but synergistic mechanisms produces greater weight loss than either alone.

The REDEFINE Phase 3 program is ongoing. Early data has pointed toward approximately 25% weight loss at 68 weeks — above tirzepatide's 22.5% and approaching retatrutide's Phase 2 numbers. REDEFINE 1 results are expected in 2025, with any FDA submission and review period following. CagriSema would be a fixed-dose combination injection — meaningful because it eliminates the need to manage two separate agents for patients on both semaglutide and an amylin pathway drug.

The pipeline: amycretin

Amycretin is a single molecule — not a combination of two existing drugs, but a new chemical entity — that incorporates GLP-1 receptor agonism and amylin receptor agonism within one structure. Novo Nordisk's rationale is that a single molecule combining both mechanisms may have better pharmacokinetic properties and fewer manufacturing complexities than a co-formulated combination like CagriSema.

Phase 2 data for the injectable version has been described as "very promising," with weight loss numbers in the same territory as CagriSema. An oral version of amycretin is also in development — oral peptide-amylin combination delivery would be technically challenging but if achievable would represent a significant advance. Phase 3 has not yet produced full data; amycretin is likely 3–4 years from approval if development continues without setbacks.

The pipeline: danuglipron

Danuglipron (Pfizer) is a non-peptide small molecule GLP-1 agonist in the same mechanistic category as orforglipron. Earlier twice-daily formulation showed efficacy but an elevated rate of GI side effects relative to comparators, prompting Pfizer to reformulate as a once-daily extended-release version. That reformulation is in Phase 3. Danuglipron does not yet have a clear approval timeline but remains active in development.

The pipeline: mazdutide

Mazdutide is a GLP-1/glucagon dual agonist being developed by Innovent Biologics with Eli Lilly involvement, primarily in China but with global aspirations. Phase 3 trials are ongoing. Early Phase 2 data showed weight loss in the 12–15% range, with a more pronounced effect on liver fat than some other agents — potentially relevant for patients with metabolic-associated steatotic liver disease (MASLD). Global approval would require a full FDA submission and review process that has not been initiated as of 2026.

The honest timeline caveat

Pipeline announcements routinely compress time. The path from "Phase 3 started" to "FDA approved and available at pharmacy" typically runs 2–4 years — sometimes longer if the agency requests additional data. CagriSema and retatrutide are the most advanced, with Phase 3 data either recently reported or expected imminently. But Phase 3 data publication, NDA submission, FDA review (typically 6–12 months after submission), approval, and commercial launch are sequential steps, each with its own timeline. A drug posting impressive Phase 2 numbers today is realistically 3–5 years from being in your medicine cabinet. Adjust your expectations for anything not yet in Phase 3 completion accordingly.

The direction everything is heading

Two trends are visible across every drug in both the approved category and the pipeline. First: oral delivery is becoming standard. The approval of orforglipron and the Wegovy pill, plus pipeline oral agents including amycretin oral formulation, signals that injection-only delivery is a transitional phase rather than a permanent feature of this drug class. Second: efficacy is converging toward surgical weight loss territory. Retatrutide at 24.2% and CagriSema at approximately 25% are within the range of sleeve gastrectomy (typically 25–30% excess weight loss). If Phase 3 confirms those numbers, pharmacotherapy will match surgery for average weight loss outcomes — a development that would meaningfully change the risk-benefit calculus for patients who currently choose surgery partly because medication options were less effective.

Frequently Asked Questions

What is the difference between the Wegovy pill and orforglipron?
The Wegovy 50mg pill contains semaglutide (a peptide analogue) delivered with SNAC technology — it requires a 30-minute fast and minimal water before dosing. Orforglipron (Foundayo) is a non-peptide small molecule that can be taken with or without food. Both achieve similar weight loss (~14–15%), but orforglipron has meaningfully fewer adherence constraints.

How close is retatrutide to approval?
Retatrutide is in Phase 3 trials with data expected in late 2025 or 2026. An NDA submission, FDA review period, and commercial launch would follow — realistically adding 1–2 years. A 2027 availability estimate is plausible if Phase 3 data is strong and no additional studies are requested.

Is CagriSema available yet?
Not as of 2026. REDEFINE Phase 3 data has been emerging, but full regulatory submission and FDA review are still pending. Approval in 2026 or early 2027 is possible but not confirmed.

Will any of these new drugs work if semaglutide stopped working?
Potentially yes. Tirzepatide (already approved) adds GIP agonism and produces higher weight loss than semaglutide in people who tolerated or tried semaglutide. Multi-mechanism agents like retatrutide and CagriSema add further pathways. A drug that targets GLP-1R plus two other receptors is pharmacologically distinct from a pure GLP-1 agonist, and there is clinical rationale for stepping up.

Are these new drugs safer than older ones?
Safety data for newly approved agents is necessarily more limited than for drugs that have been on the market for years. Oral semaglutide 50mg and orforglipron have completed Phase 3 safety assessments, but post-marketing surveillance over years of broad use will provide a fuller picture. The pipeline drugs have even more limited long-term safety data until Phase 3 completes.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.